116 related articles for article (PubMed ID: 30059212)
21. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
22. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
23. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
24. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
25. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
26. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
28. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
29. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
30. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.
Ferry G; Moulharat N; Pradère JP; Desos P; Try A; Genton A; Giganti A; Beucher-Gaudin M; Lonchampt M; Bertrand M; Saulnier-Blache JS; Tucker GC; Cordi A; Boutin JA
J Pharmacol Exp Ther; 2008 Dec; 327(3):809-19. PubMed ID: 18755937
[TBL] [Abstract][Full Text] [Related]
31. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions.
Benesch MG; Ko YM; McMullen TP; Brindley DN
FEBS Lett; 2014 Aug; 588(16):2712-27. PubMed ID: 24560789
[TBL] [Abstract][Full Text] [Related]
32. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
[TBL] [Abstract][Full Text] [Related]
33. Ultrafast and Predictive Mass Spectrometry-Based Autotaxin Assays for Label-Free Potency Screening.
Bretschneider T; Luippold AH; Romig H; Bischoff D; Klinder K; Nicklin P; Rist W
SLAS Discov; 2017 Apr; 22(4):425-432. PubMed ID: 28328321
[TBL] [Abstract][Full Text] [Related]
34. Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice.
Engler H; Machemer TR; Schluep T; Wen SF; Quijano E; Wills KN; Harper AE; Maneval DC; Conroy SE
Mol Ther; 2003 Apr; 7(4):558-64. PubMed ID: 12727120
[TBL] [Abstract][Full Text] [Related]
35. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
36. The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin.
Gendaszewska-Darmach E; Laska E; Rytczak P; Okruszek A
Bioorg Med Chem Lett; 2012 Apr; 22(8):2698-700. PubMed ID: 22460025
[TBL] [Abstract][Full Text] [Related]
37. Development of autotaxin inhibitors: A series of tetrazole cinnamides.
Thomson CG; Le Grand D; Dowling M; Beattie D; Elphick L; Faller M; Freeman M; Hardaker E; Head V; Hemmig R; Hill J; Lister A; Pascoe D; Rieffel S; Shrestha B; Steward O; Zink F
Bioorg Med Chem Lett; 2021 Jan; 31():127663. PubMed ID: 33160025
[TBL] [Abstract][Full Text] [Related]
38. PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability.
St-Cœur PD; Ferguson D; Morin P; Touaibia M
Arch Pharm (Weinheim); 2013 Feb; 346(2):91-7. PubMed ID: 23300119
[TBL] [Abstract][Full Text] [Related]
39. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
40. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
